GlassScriptPhysician profile
Harry A Hill
NPI 1700033982
$3,559.71
in general payments reported to CMS, 2019-2025
16 companies · $762 in 2025
The $762 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $652 · 2022: $936 · 2023: $768 · 2024: $442 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.62 |
| Education | $116.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,120.20 | 2021-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $659.49 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $347.06 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $301.80 | 2021-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $228.71 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $198.59 | 2021-2025 | Fanapt |
| Abbvie INC. | $128.65 | 2021-2024 | |
| Alkermes, INC. | $109.19 | 2021-2025 | Lybalvi |
| Lundbeck LLC | $99.60 | 2021-2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $99.27 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $93.06 | 2021-2022 | |
| Axsome Therapeutics, INC. | $51.26 | 2023-2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $41.49 | 2022-2023 | Jornay Pm |
| Indivior INC. | $29.14 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.90 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $23.30 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.